Overview

Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in metastatic breast cancer
Phase:
Phase 3
Details
Lead Sponsor:
Athenex, Inc.
Kinex Pharmaceuticals Inc
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel